Literature DB >> 28832860

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value.

Daniel B Mark1, Ilana Richman2, Mark A Hlatky3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28832860     DOI： 10.1001/jamacardio.2017.2911

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  2 in total

1.  Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.

Authors:  Gregg C Fonarow; Ben van Hout; Guillermo Villa; Jorge Arellano; Peter Lindgren
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

2.  Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.

Authors:  Lisandro D Colantonio; Keri L Monda; Robert S Rosenson; Todd M Brown; Katherine E Mues; George Howard; Monika M Safford; Larisa Yedigarova; Michael E Farkouh; Paul Muntner
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.